Depression Treatment: Can RR-HNK Offer Rapid Relief?

What is RR-HNK, and why are researchers studying it?

Ketamine research has encouraged scientists to search for treatments that relieve depression more quickly than conventional antidepressants. One candidate is (2R,6R)-hydroxynorketamine, abbreviated RR-HNK, a substance the body produces when processing ketamine. Researchers are studying the compound as a medication in its own right. The NIMH report behind this headline was published on October 24, 2024; it described an early safety milestone rather than a newly demonstrated depression treatment. [NIMH research highlight](https://www.nimh.nih.gov/news/science-updates/2024/new-hope-for-rapid-acting-depression-treatment).

Animal experiments provided a biological rationale: RR-HNK produced antidepressant-like effects involving AMPA receptors, which participate in signaling by the brain chemical glutamate. Those experiments suggested that some potentially useful effects could occur without ketamine-like changes in perception. However, animal behavior cannot establish whether a medication relieves human depression, and the mechanism responsible for any clinical benefit still requires investigation. [NIMH account of the preclinical research](https://www.nimh.nih.gov/news/science-updates/2016/ketamine-lifts-depression-via-a-byproduct-of-its-metabolism).

What did the first human RR-HNK study actually show?

The investigation enrolled 74 healthy adults aged 18–65, with 55 receiving intravenous RR-HNK and 19 receiving placebo across its study components. Researchers examined single doses, repeated administration, and how the compound moved through the body. They reported no serious adverse events and no observed sedation or dissociation, the sense of disconnection from oneself or one's surroundings associated with ketamine. These findings supported further clinical investigation. [Raja and colleagues, Clinical Pharmacology & Therapeutics](https://doi.org/10.1002/cpt.3391).

The distinction between tolerability and effectiveness is central to interpreting the results. Participants did not have depression, so the study could not show whether RR-HNK improved mood, how quickly an antidepressant effect might appear, or how long it might last. A small, short study also cannot exclude uncommon complications or establish safety during prolonged treatment. The findings therefore support testing the drug in patients; they do not establish that it is broadly safe or clinically superior to ketamine. [Published phase 1 study](https://doi.org/10.1002/cpt.3391).

What does RR-HNK research mean for people with depression?

A separate NIMH-sponsored study, registered as NCT06511908, is investigating HNK in adults with major depressive disorder. Its registry record, updated June 16, 2026, lists recruitment and no posted results. That distinction matters: a registered trial describes a question researchers are testing, not a successful treatment outcome. Clinically useful evidence would need to establish symptom improvement, the durability of benefit, and the balance between benefits and adverse effects. [ClinicalTrials.gov study record](https://clinicaltrials.gov/study/NCT06511908).

RR-HNK should also be distinguished from esketamine nasal spray, sold as Spravato. FDA prescribing information permits esketamine for treatment-resistant depression in adults, either alone or with an oral antidepressant. Administration requires a certified healthcare setting and observation for at least two hours because of risks including sedation, dissociation, and respiratory depression. Approval of esketamine does not establish the effectiveness or safety of a different ketamine-related compound. [FDA prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf).